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ABSTRACT
Objective: The transfer of anti-human immunodeficiency virus (HIV) drugs has been studied in the
ex vivo human placental model. There is a paucity of information on the placental transfer of these
drugs because of ethical considerations and the expense involved in the use of the non-human
primate model.
Methods: The standardized exvivo human placental model was used in these studies and the
clearance index in relationship to antipyrine was used to determine the role of transfer of non-
nucleosides, nucleosides, and a protease inhibitor. Several of the nucleosides and ritonavir were
combined with zidovudine (AZT) to determine the effect of the combinations.
Results: All non-nucleosides, nucleosides, and the protease inhibitor were found to cross the
human placenta by simple diffusion, although at variable rates. Ritonavir did not diffuse as rapidly
as the nucleosides, but some diffusion was noted at peak concentrations.
Conclusions: Ex vivo perfusion studies agree with those determined in the non-human primate
model and with data from existing clinical trials. Infect. Dis. Obstet. Gynecol. 5:310-315, 1997.
(C) 1998 Wiley-Liss, Inc.
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n 1995, of the more than 500,000 cases of sero-
positive human immunodeficiency virus (HIV) in
the United States, 14.5% or more than 72,000
women were HIV positive. Also, in 1993, 6,530
HIV-infected women gave birth to an estimated
1,630 HIV-infected infants, z In addition, there
were an estimated 12,240 HIV-infected children
living in 1994. With these statistics, it is obvious
that perinatal transmission of HIV is an important
problem which needs to be addressed. With the
completion of the Pediatric AIDS Clinical Trials
Group Protocol 076, it was determined that the use
of azidothymidine (AZT) reduced the transmission
rate of HIV from mother to infant from approxi-
mately 24% to about 8%.3 With this reduction in
perinatal transmission, the use of other nucleoside
and non-nucleoside inhibitors alone and in combi-
nation with protease inhibitors during pregnancy
may become extremely important.
Because HIV mutates very readily and becomes
resistant to single drug therapy, the use of combi-
nation therapy with two nucleoside inhibitors, and
more aggressively two nucleoside inhibitors and a
protease inhibitor, may be necessary for the pre-
vention of perinatal transmission of the virus. The
purpose of this review is to examine the published
perfusion model data involving non-nucleoside and
nucleoside inhibitors alone and in combination.
Studies on the combination of a nucleoside inhibi-
tor and a protease inhibitor also are included.
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LITERATURE REVIEW
Studies on the pharmacology and teratology of the
anti-HIV nucleosides in animal models and ex vivo
systems are useful prior to the use of these inhibi-
tors for treatment of HIV positive pregnant
women. Among the nucleosides involved in tera-
tology studies were 2’-3’-dideoxycytidine (ddC),
2’-3-dideoxyinosine, which is now didanosine
(ddI), and AZT. In rat embryo culture studies, a
minimum of40% of embryos developed abnormal-
ity with AZT, while other drugs showed a higher
interference with embryonic development. In ex-
periments with pregnant rats treated with 200 mg/
kg of each drug 3 times/day (600 mg/kg), there
were no subsequent abnormal developments noted
on day 10.4,5 However, subsequent studies did
identify pregnancy resorption at dose.levels 15
times the normal human dose of 300 mg BID
(2,250 mg/kg) under similar conditions. This is con-
sistent with several studies showing the embryole-
thal effect of postimplantation in rats and preim-
plantation of mouse embryos.4-8
The current American College of Obstetricians
and Gynecologists (ACOG) recommendation for
the treatment of pregnant women is 100 mg of
zidovudine (AZT) 5 times/day beyond 14 weeks of
gestation and continued throughout pregnancy.
Treatment during labor consists of intravenous zid-
ovudine with a 2 mg/kg loading dose over h fol-
lowed by a continuous infusion of mg/kg/h. Neo-
natal treatment consists of 2 mg/kg of zidovudine
for the first 6 weeks of life beginning 8-12 h after
birth.9 With new guidelines about to be published,
the above therapy is probably inadequate, as HIV
drug resistance is known to develop on single drug
therapy. The revisions include treatment with two
nucleosides, and possibly two nucleosides and a
protease inhibitor.
Ex Vivo Perfusion Model
The model utilized in this study has been used
successfully by other investigatiors to determine
the transport of amino acids, lipids, electrolytes,
metabolites, antimicrobial drugs, and anti-HIV
compounds. 1,11 The criteria for the standardiza-
tion of this model involve the use of standard me-
dia, monitoring fetal pressure, temperature, pH,
and Oz content, and the use of the reference com-
pound antipyrine. The use of antipyrine, a freely
diffusible small molecule, determines the mater-
nal-fetal match in the isolated cotyledon as well as
the basis for the clearance index (Ci), which is a
percentage of the study compound based on the
transfer of antipyrine. Thus the higher the Ci, the
more readily the compound is diffusible and
crosses the placenta. The formula used is as fol-
lows:
TF (CFv CFA)/(CMA CFA
where TF the transport fraction; C concentra-
tion; M maternal perfusate; F fetal perfusate; A
artery; and V vein.
In our study, the steady-state experiment in
which the maternal and fetal circulation was not
recirculated, the fetal artery contained none of the
test substance, therefore:
rF CFv/CMA
and the transport fraction was used to derive the
clearance (C1) of the compound studied, where Q is
the flow rate of the fetal circulation.
C1 TF x Q.
Similar calculations were done with the test com-
pound, in this case the anti-HIV drugs, so that the
Ci is determined.
Ci=
clearance of test compound
clearance ofantipyrine
In general, several concentrations of a test drug
were used to coincide with the therapeutic trough
and peak of the drug and a 10x concentration to
determine saturation of the placental transport (dif-
fusion) system. In addition, most concentrations
were done in at least three different placentas, lz
HIV Replication and Inhibition
HIV is in the family Retroviridae, which encom-
passes a large number of infectious agents. One of
the most important features of this family is its
replication cycle. Retroviruses replicate from a
single stranded genome of polyadenylated RNA.
The virion also contains several enzymes important
in its replication, which include reverse transcrip-
tase, ribonuclease, and protease. The replication










Fig. I. Structural change in deoxycytidine to form ddC and 3TC, which causes viral RNA chain termination.
process involves cell entry, the coding of the viral
RNA into double stranded DNA by reverse tran-
scription, and ribonuclease. Once the process is
completed, the viral DNA is integrated into the
host DNA as a provirus where new viral RNA is
formed and viral proteins are synthesized, leading
to the completion and release of the virus. 13
The focus of anti-HIV therapy has been in the
prevention of transcription by the reverse transcrip-
tase and in the inhibition of the protein cleavage at
the termination of the formation of the virion; thus
the terms "reverse transcriptase inhibitors" (both
nucleoside and non-nucleoside) and "protease in-
hibitors." By altering the structure of natural
nucleotides such as the removal of a free 3’OH
group or the insertion of a sulfur atom in the ribose
sugar of ddC, the compound may have an addi-
tional inhibitor effect. Intracellularly, 2’-dideoxy-
3’-thiacytidine (3TC) is converted by cellular
enzymes to the 5’ triphosphate metabolite. By
competing with the natural substrate 3TC 5’ tri-
phosphate and its incorporation into viral DNA, the
analog (3TC) prevents formation of the 5’3’ phos-
phodiester linkage essential for DNA chain elon-
gation, therefore resulting in viral DNA termina-
tion. When these compounds are incorporated into
growing chains, no further nucleosides can be
added (chain termination). The alterations are
shown in Figure 1.13-15. These compounds are in-
hibitory because their alterations cause changes in
molecular configuration, which causes transcription
termination.
Non-nucleoside inhibitors may inhibit reverse
transcriptase by acting as the phosphate group on
the sugar structure of the nucleotide, thus prevent-
ing incorporation into viral DNA.
Protease inhibitors include a wide variety of
compounds which inhibit HIV protease (aspartic
proteinase) activity. One such compound, ritonavir,
has a molecular weight of 720 and binds competi-
tively to the protease enzyme, to cause the produc-
tion of immature virons. Mutations that occur in
the viral genome may be related to resistance to
protease inhibitors.
Ex Vivo Human Placental Model and
Nucleoside Inhibitors
Studies done with AZT used the isolated single
cotyledon model with antipyrine as a freely diffus-
ible marker. 16-18 Using these methods, it is pos-
sible for several laboratories to compare the rate of
transport of various drugs. Several ex vivo human
placental studies reported that the Ci of AZT was
0.24 ___
0.04 to 0.29 ___
0.06.16-18 Although the pla-
cental perfusion model cannot be compared to the
pregnant woman for pharmacokinetic parameters,
unusual transfer or placental effects may be de-
tected.
In vivo AZT pharmacokinetic studies in three
pregnant HIV positive women were done at 19, 30,
and 33 weeks with no unusual side effects. Amni-
onic fluid levels were high in the cord blood levels,
suggesting fetal renal excretion and accumulation
of the drug by the infant in the amnionic fluid.
In addition, cord blood levels were 113-127%
higher than maternal levels. 19 These data confirm
transplacental transport and fetal accumulation in
both the in vivo and the ex vivo human placental
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TABLE I. Ex vivo placental transfer of anti-HIV nucleosides
Trade name
Concentration
Nucleoside inhibitor (lg/ml) Ci
b
Retrovir2z
Glaxo Wellcome (Research Triangle Park, NC)
Videx
Bristol-Myers Squibb (Syracuse, NY)
Hivid






AZT 10 0.29 + 0.04
2’-3’-Dideoxyinosine (ddl) 0.14 + 0.03
ddl 10 0.15 + 0.04
2’-3’-Dideoxycytidine (ddC) 0.22 + 0.06
ddC 10 0.23 + 0.03
2’-3’-Didehydro-3’-deoxythymidine (d4T) 0.24 + 0.07
d4T 10 0.235 + 0.045
(-) 2’-Dideoxy-3’-thiacytidine (3TC) 1.4 0.23 + 0.14
3TC 14.0 0.14 _+ 0.06
aApproximate concentration.
bStandard deviation.
models. Other nucleoside compounds that are ei-
ther available for treatment of HIV infections or are
in various phases of clinical development and have
been studied in the ex vivo human perfusion
model include ddI, ddC, 2’-3’-didehydro-3’-
deoxythymidine (d4T), and 3TC, of which the lat-
ter may only be used in combination with other
nucleoside inhibitors including AZT.z,zl The Ci
of these compounds is depicted in Table 1.
Further studies, with these nucleoside inhibi-
tors indicated there were no significant changes in
the Ci when ddl, ddC, d4T, and 3TC were used in
combination with therapeutic and 10x concentra-
tions of AZT. When endogenous bases and the
inhibitor dipyridamole were added to placental
perfusion studies with these anti-HIV nucleoside
inhibitors, there were no changes in the Ci, sug-
gesting no transport system and no adverse effects
of the combination. Thus, the compounds cross
from the maternal to the fetal compartment by
simple diffusion. 16-zl
In a recent open label pilot study (NUCB2018)
in South Africa using 3TC alone and AZT along
with 3TC in combination, 20 HIV pregnant women
were given 8 mg/kg/day (300 mg BID) of 3TC or 4
mg/kg/day (150 mg/kg BID) 3TC plus 8 mg/kg/day
ofAZT at 38 weeks and continuing through week
postpartum. There was no viral RNA found in all
20 newborns at birth and 2 weeks postpartum. Ma-
ternal and fetal blood concentrations were similar
to the levels used in the ex vivo human placental
studies, and similarly, there were no changes in the
blood concentrations when 3TC and AZT were
used in combination. These data are promising, but
further larger long-term studies are needed,z3
In Vivo Non-Human Primate Studies
Placental perfusion studies must be done in either
non-human primates or in ex vivo perfusion models
because anatomically no other animal has a discoi-
dal placenta which has a villous fetomaternal inter-
digitation, a hemomonochorial barrier, and is mul-
tivillous, z4 When ddI was infused into the ma-
caques at human doses along with antipyrine, a Ci
of 0.09 + 0.04 was determined, which was not dif-
ferent from studies in the ex vivo perfusion model
(0.14 +_ 0.05). 18’25 The in vivo studies also indicated
that with constant infusion there was no accumu-
lation of ddI in the fetus.
Stavudine (d4T) administered to pregnant pig-
tailed macaques (Macaca nemestrina) resulted in an
antipyrine Ci of 0.23 + 0.04, which was identical to
the results reported in the ex vivo human placenta
model,z,z6 Although the data in animal studies are
limited, there is no conflict with the data from the
ex vivo human placental model. The disadvantage
of the ex vivo human placental model relates to the
lack of actual pharmacokinetics of the drugs as the
time to peak plasma concentration (tl/z), peak
plasma concentration (Cmax), and bioavailability.
Protease Inhibitors and Ex Vivo
Perfusion Model
With the recent Food and Drug Administration
(FDA) approval of four new protease inhibitors for
the treatment of HIV-1 infections, these drugs and
their approval represent a major advance in the
management of HIV infection.27 These new drugs
include saquinavir mesylate (Invirase), ritonavir
(Norvir), indinavir sulfate (Crixivan), and nelfinavir
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(Virocept). However, these drugs are not without
adverse reactions, as they have a wide variety of
side effects and have complicated drug interactions
with other medications used in the treatment of
AIDS and other diseases of the adult patient. Be-
cause of these toxic properties in the use of these
potent inhibitors alone and in combination with
other inhibitors, there is a need for long-term stud-
ies in the in vivo non-human primate and short-
term studies in the ex vivo human placental model.
The toxicity and teratology of these drugs may pre-
vent the use of protease inhibitors in the pregnant
patient. To date there has been only one study
done with ritonavir in the ex vivo human placental
model,z8 In this study, the Ci and trough levels
were below the sensitivity of detection by high
pressure liquid chromatography. At therapeutic
peak concentrations the Ci was 0.138 _+ 0.04, which
suggests there was little transport across fetal mem-
branes at low levels, but the drug does cross at peak
concentrations. However, there was little accumu-
lation when the system was closed to allow for ac-
cumulation in the fetal circulation for h. The
addition of AZT had no effect on the transfer of
ritonavir at either peak or trough concentrations,z8
Non-Nucleoside Reverse
Transcriptase Inhibitors
The non-nucleoside reverse transcriptase inhibitor
used in these studies was bisheteroypiperazine (U-
87201-E).29 The studies with U-87201-E suggest a
rapid diffusion of the drug at therapeutic concen-
trations of 1.0 and 20 pg/ml with a Ci of 0.72 _+ 0.17.
This Ci is twice that of AZT, and 5 times that of
ddI. Placental tissue concentrations were near
those of the maternal blood concentration, suggest-
ing saturation.29
CONCLUSIONS
The ex vivo human placental model has provided
basic information as to the transport of a wide va-
riety of anti-HIV compounds. In application to
clinical practice, the placental perfusion model has
provided information on the use of multiple drugs
without adverse reactions to the transfer of other
anti-HIV compounds.
3 This has been substanti-
ated with the protocol NUCB2018 with AZT and
3TC, in which perfusion experiments predicted no
adverse reactions and demonstrated that the drugs
were readily transported across the placental mem-
branes. At this point, it may be concluded that all of
the compounds thus far tested cross the placental
barrier except ritonavir, which appears to be lim-
ited. Because there is a wide variation in transfer
and these data agree with the non-human primate
model, it is an important preliminary step to deter-
mine the transport and toxicity of these compounds
prior to clinical trials with these drugs alone and in
various combinations.
DISCUSSION
Questions that need to be answered concerning the
use of single or multiple anti-HIV drugs during
pregnancy include the following1:
1. What are the long-term effects of these drugs on
the mothers and fetuses of future pregnancies?
Since anti-HIV drug therapy forpregnant aomen is
in its early stages, it is difficult to predict the effect on
futurepregnancies, but in allprobability there will be
no problems.
2. Does the reduction in viral load to non-
detectable levels in blood and tissue mean the
virus has been totally eradicated? .Total elimina-
tion of the virus is not possible waith existing treat-
ment, as the virus is integrated into the human ge-
home; only replication of the virus is prevented.
3. Can these compounds be used in the first and
second trimesters of pregnancy? Probably not the
fi:rt trimester, but d’nitely in the second trimester. A
registerfor anti-HIV drugs is being established simi-
lar to the use of acyclovir when early treatment aas
administeredprior to, at, or after conception.
4. With the possibility of total elimination of HIV
from blood and tissue by the use of combination
(triple therapy), is pregnancy still an option?
These drugs do not destroy the virus, theyjustprevent
viral replication.
5. The issue of standard of care must be addressed;
if AZT therapy alone is good enough in non-
Even more aggressive anti-HIV therapy is being recommended in the Federal Register in the draft of the "Guidelines for the
Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents" and the U.S. Public Health Recommendations for
Use of Antiretroviral Drugs During Pregnancy for Maternal Health and Reduction of Perinatal Transmission of Human
Immunodeficiency Virus Type 1 in the United States; request for comment.
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pregnant patients, why is it not good enough for
pregnant women? Because the virus mutates
readily, single therapy is not adequate. The CDC and
FDA willprobably recommend triple therapy to pre-
vent development ofHIV resistance.
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